In conclusion, the novel 11-DRL signature model can help predict the prognosis of patients with HNSCC, with ALMS1-IT1 demonstrating potential as a therapeutic target in HNSCC. The gene discussed is ALMS1; the disease is head and neck squamous cell carcinoma.